US 12,404,298 B2
Glucocorticoid receptor agonists
Adel Ahmed Rashad Ahmed, Fishers, IN (US); Joshua Ryan Clayton, Fishers, IN (US); Jose Eduardo Lopez, Fishers, IN (US); William Thomas McMillen, Indianapolis, IN (US); Ryan Edward Stites, Indianapolis, IN (US); Takako Wilson, Indianapolis, IN (US); and Jacqueline Mary Wurst, Indianapolis, IN (US)
Assigned to Eli Lilly and Company, Indianapolis, IN (US)
Filed by Eli Lilly and Company, Indianapolis, IN (US)
Filed on Sep. 8, 2023, as Appl. No. 18/463,293.
Application 18/463,293 is a continuation of application No. 17/700,943, filed on Mar. 22, 2022, granted, now 11,787,834.
Claims priority of provisional application 63/260,451, filed on Aug. 20, 2021.
Claims priority of provisional application 63/164,613, filed on Mar. 23, 2021.
Prior Publication US 2024/0018182 A1, Jan. 18, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C07J 71/00 (2006.01)
CPC C07J 71/0031 (2013.01) 25 Claims
 
1. A compound of the formula:

OG Complex Work Unit Chemistry
wherein R is H or

OG Complex Work Unit Chemistry
R1 is halogen, CN, C1-C3 alkyl, C3-C6 cycloalkyl, C1-C3 alkoxy, C2-C3 alkenyl, OCF3,

OG Complex Work Unit Chemistry
R2 is halogen, C1-C3 alkyl, C1-C3 alkoxy, or C2-C3 alkenyl; and
X is O, OCH2, OCH2CH2, CH2O, SCH2, CH2S, CH2, NHCH2, CH2NH, N(CH3)CH2, CH2CH2, C≡C, or a bond, or a pharmaceutically acceptable salt thereof.